Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A, Devreker F, Dechene J, Ferster A, Veys I, Fastrez M, Englert Y, Demeestere I
Department of Obstetrics and Gynaecology, Fertility Clinic, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium Present address: Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, Brussels 1200, Belgium.
Department of Obstetrics and Gynaecology, Fertility Clinic, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium Present address: Instituto Marquez, Assisted Reproduction Service, Manuel Girona 33, MASIA, Barcelona 08034, Spain.
Hum Reprod. 2014 Sep;29(9):1931-40. doi: 10.1093/humrep/deu158. Epub 2014 Jun 22.
Do the benefits of ovarian tissue cryopreservation outweigh the risks for patients seeking to preserve fertility before gonadotoxic treatment in various indications?
In >90% of the patients undergoing cryopreservation of ovarian tissue, oncological treatment was associated with a reduced ovarian reserve and in 30% of patients, premature ovarian failure (POF) occurred within 5 years.
Ovarian tissue cryopreservation is an effective fertility preservation option, especially for pre-pubertal patients and patients who have a short time between diagnosis of a disease and gonadotoxic treatment.
STUDY DESIGN, SETTING, DURATION: This study retrospectively analysed ovarian function and fertility recovery rates, as well as ovarian tissue characteristics, of patients who underwent ovarian tissue cryopreservation at Erasme Hospital between 1999 and 2011.
PARTICIPANTS/MATERIALS, SETTINGS, METHODS: A total of 225 patients referred from 15 Belgian oncological units underwent cryopreservation of ovarian tissue before gonadotoxic therapy for malignant or benign diseases. There were 28 patients (12.4%) who died during follow-up due to recurrence of disease. One severe adverse event occurred during anaesthesia for ovarian tissue collection, leading to the death of the patient. Ovarian function and fertility outcomes were available for 114 patients including 13 girls who were pre-pubertal at the time of the procedure. Eight patients had undergone ovarian tissue transplantation in order to restore their fertility after remission of the disease.
Breast cancer and haematological disease were the most frequent indications for ovarian tissue cryopreservation. Overall, 90% of post-pubertal patients were diagnosed with poor ovarian reserve (AMH < 0.5 ng/ml) after a mean of 50 months of follow-up (11-125 months), including 30% with POF (FSH > 40 IU/ml). Breast cancer patients had a lower rate of POF than did post-pubertal patients with haematological diseases (11 versus 34.5%, respectively), despite the older age (mean 31 versus 23.5 years old, respectively) of the breast cancer patients. Ovarian function returned in 71 post-pubertal patients without the need for grafts of cryopreserved tissue. Spontaneous pregnancies were reported for 33 of them, leading to 34 live births. Among the 13 pre-pubertal patients who reached pubertal age during the follow-up, 10 had POF. Eight patients received cryopreserved ovarian grafts to reverse POF and three of them have already become pregnant.
LIMITATIONS, REASONS FOR CAUTION: This study is a retrospective analysis. The cohort was not compared with a control group of patients who did not undergo the procedure.
After careful evaluation of the surgical risks, ovarian tissue cryopreservation can be proposed as an efficient option to preserve the fertility of children and young adults facing gonadotoxic therapies. However, alternative procedures such as oocyte or embryo cryopreservation should be considered as first options especially for older patients or if there is high risk of neoplastic cells within the ovaries.
STUDY FUNDING/COMPETING INTEREST: This study was supported by the Télévie, FNRS-FRSM and Fondation Belge contre le cancer. There are no competing interests to report.
对于因各种适应症而寻求在性腺毒性治疗前保留生育能力的患者,卵巢组织冷冻保存的益处是否大于风险?
在接受卵巢组织冷冻保存的患者中,超过90%的患者在接受肿瘤治疗后卵巢储备功能下降,30%的患者在5年内出现卵巢早衰(POF)。
卵巢组织冷冻保存是一种有效的生育力保存方法,尤其适用于青春期前患者以及疾病诊断与性腺毒性治疗间隔时间较短的患者。
研究设计、地点、时间:本研究回顾性分析了1999年至2011年间在伊拉斯谟医院接受卵巢组织冷冻保存的患者的卵巢功能、生育恢复率以及卵巢组织特征。
参与者/材料、地点、方法:共有225名来自15个比利时肿瘤科室的患者在接受恶性或良性疾病的性腺毒性治疗前进行了卵巢组织冷冻保存。有28名患者(12.4%)在随访期间因疾病复发死亡。在一次卵巢组织采集麻醉过程中发生了1例严重不良事件,导致患者死亡。114名患者的卵巢功能和生育结局数据可得,其中包括13名在手术时为青春期前的女孩。8名患者在疾病缓解后接受了卵巢组织移植以恢复生育能力。
乳腺癌和血液系统疾病是卵巢组织冷冻保存最常见的适应症。总体而言,青春期后患者在平均50个月(11 - 125个月)的随访后,90%被诊断为卵巢储备功能差(抗苗勒管激素<0.5 ng/ml),其中30%患有卵巢早衰(促卵泡生成素>40 IU/ml)。乳腺癌患者的卵巢早衰发生率低于青春期后血液系统疾病患者(分别为11%和34.5%),尽管乳腺癌患者年龄更大(平均分别为31岁和23.5岁)。71名青春期后患者的卵巢功能恢复,无需移植冷冻保存的组织。其中有33例自然怀孕,产下34名活婴。在随访期间进入青春期的13名青春期前患者中,10名患有卵巢早衰。8名患者接受了冷冻保存的卵巢移植以逆转卵巢早衰,其中3名已怀孕。
局限性、注意事项:本研究为回顾性分析。该队列未与未接受该手术的对照组患者进行比较。
在仔细评估手术风险后,卵巢组织冷冻保存可作为一种有效的选择,用于为面临性腺毒性治疗的儿童和年轻成人保留生育能力。然而,替代方法如卵母细胞或胚胎冷冻保存应被视为首选,尤其是对于年龄较大的患者或卵巢内存在肿瘤细胞高风险的情况。
研究资金/利益冲突:本研究由电视募捐、比利时国家科学研究基金 - 医学研究基金和比利时抗癌基金会资助。无利益冲突声明。